Details of the Drug Reposition

General Information of This Drug (ID: DMK0QDO)

Drug Name
CC-90002   DMK0QDO
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [1]
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [1]
leukaemia DISS7D1V 2A60-2B33 Phase 1 [2]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02641002) A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)